A1G
0.522
65.7%
CAN
0.009
-18.2%
ERA
0.003
50%
CYQ
0.005
-16.7%
RBRDA
0.015
36.4%
IPT
0.005
-16.7%
EDU
0.82
35.5%
IBX
0.022
-15.4%
M4M
0.008
33.3%
EE1
0.006
-14.3%
GR8
0.21
31.3%
G88
0.006
-14.3%
PIQ
0.52
30%
OVT
0.006
-14.3%
AYT
0.005
25%
HYD
0.013
-13.3%
PGY
0.005
25%
T92
0.052
-13.3%
RLG
0.005
25%
RB6
0.11
-12%
TMX
0.005
25%
FAL
0.555
-11.9%
WLD
0.016
23.1%
TNC
0.56
-11.1%
YUG
0.065
22.6%
TSL
0.008
-11.1%
APC
0.012
20%
PNR
4.815
-10.7%
VRC
0.006
20%
DTZ
0.05
-10.7%
BOC
0.73
19.7%
ASQ
0.018
-10%
ALR
0.025
19%
OLI
0.009
-10%
RGL
0.007
16.7%
SPQ
0.009
-10%
8CO
0.029
16%
TIO
0.18
-10%
TTT
0.23
15%
CHN
1.702
-9.7%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Cleo Diagnostics (ASX:COV): Bringing to market a simple blood test

Cleo Diagnostics (ASX:COV) is attempting to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in nonmalignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide | Investor presentation: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02774453-3A636747